Xinliang Kong

Xinliang Kong

Auto-generated profile, based on publicly available information

Xinliang Kong

Department of Traditional Chinese Medicine, Shandong Maternal and Child Health Hospital, 250013 Jinan, Shandong, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Journal of Reproductive Immunology
Verified
Journal Article
Open access
XKXinliang Kong
Xinliang Kong
GTGuodong Tang
Guodong Tang
YLyanfeng liu
yanfeng liu
ZZZhibo Zheng
Zhibo Zheng
YLYing Li
Ying Li
FYFei Yan
Fei Yan
Previous studies of intrauterine infusion therapy in recurrent implantation failure (RIF) patients have shown conflicting results, and there is a lack of head-to-head horizontal comparisons between different drugs. This study aimed to assess the effectiveness of four intrauterine infusion drugs, including human chorionic gonadotropin (HCG), granulocyte colony-stimulating factor (G-CSF), peripheral blood mononuclear cells (PBMCs) and autologous platelet-rich plasma (PRP), in improving pregnancy outcomes in RIF patients through the network meta-analysis. Randomized controlled trials (RCTs) of preimplantation intrauterine infusion for RIF were searched in the Cochrane Library, Embase, Medline and CINAHL. Meanwhile, relevant data were extracted and Stata 15.0 software was applied to statistical analysis. A total of 21 studies with a sample size of 2917 cases were included in this study. Clinical pregnancy rate network meta-analysis showed that, intrauterine infusion of all four drugs is significantly better than the blank and placebo groups, while only PRP could significantly increase live birth rate compared with the blank and placebo groups. The SUCRA plots of clinical pregnancy and live birth rates showed a higher ranking of PRP and PBMCs. Early abortion intervention analysis found that only G-CSF is significantly better than the blank and placebo groups, and the SUCRA plot of G-CSF showed the highest ranking. All these findings confirmed that all four intrauterine infusion drugs can improve pregnancy outcomes in RIF patients to varying degrees, with PRP being the most effective. Further prospective, large-scale and high-quality RCTs are still necessary to determine the exact subgroups of benefit for the different drugs.

17 March 2026 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
DTDongmei Tan
Dongmei Tan
YSYimin Shi
Yimin Shi
XKXinliang Kong
Xinliang Kong
PCPingping Cai
Pingping Cai
ZMZhaoqing Meng
Zhaoqing Meng
Objective: This review summarizes global advances in antibody-drug conjugate (ADC) research for the treatment of gynecologic cancers and highlights China’s rapidly evolving role in developing these agents, aiming to contextualize their growing impact on future therapeutic standards. Mechanism: ADCs represent a transformative class of targeted therapies, coupling monoclonal antibodies with potent cytotoxic payloads through linkers, thereby enabling selective drug delivery to tumor cells while minimizing systemic toxicity. Findings in Brief: Globally, ADCs such as mirvetuximab soravtansine and tisotumab vedotin have demonstrated significant clinical benefits in platinum-resistant ovarian and recurrent cervical cancers. Parallel progress in other ADCs has expanded therapeutic options across ovarian, endometrial, and cervical cancers. In China, ADC development is accelerating, with several domestically developed agents targeting folate receptor alpha, human epidermal growth factor receptor 2, trophoblast cell surface antigen 2, cadherin-6, nectin-4, B7 homolog 4, and epidermal growth factor receptor/human epidermal growth factor receptor 3 advancing into phase II and III trials. Early results show encouraging efficacy and safety, underscoring China’s emergence as a key contributor to global anticancer innovation. Nevertheless, variability in biomarker assay, regulatory differences, and future challenges related to pricing and equitable access remain important considerations. Conclusions: ADCs are redefining the treatment landscape for gynecologic cancers. China’s expanding pipeline, supported by domestic innovation and international collaboration, is poised to significantly influence future standards of care. Continued progress in clinical validation, regulatory alignment, and the development of diagnostic and reimbursement infrastructures will be essential to ensure that these novel therapies achieve meaningful and equitable global impact.